Skip to main content

Advertisement

SpringerLink
Log in

Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy induced alopecia

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

We evaluated the preventive effect of the antioxidant edaravone (EDR) on chemotherapy-induced alopecia (CIA) to improve quality of life in cancer patients.

Methods

Hair loss was induced by intraperitoneally administering cyclophosphamide (CPA, 75 mg/kg) to rats, and topically applying EDR ointment (100 mg/day) once daily for 16 days (when hair loss starts) or 21 days (just before hair growth). The rats were divided into four groups: control group (without CPA or EDR), EDR 0% group (CPA + EDR 0%), EDR 3% group (CPA + EDR 3%), and EDR 30% group (CPA + EDR 30%). The prevention of CIA was evaluated by the hair coverage score (five levels from 0 to 4). Furthermore, we measured the size of the hair follicle area and the expression levels of insulin-like growth factor (IGF)-1 mRNA in dermal papilla cells.

Results

The EDR 3% and EDR 30% groups exhibited higher hair coverage scores than the EDR 0% group on day 16 and day 21. On day 16, the hair follicle area in the EDR 3% and EDR 30% groups was significantly larger than that in the EDR 0% group. Furthermore, IGF-1 expression levels in the EDR 3% group were significantly higher than those in the EDR 0% group. On day 21, no significant difference was observed in hair follicle area or IGF-1 mRNA levels among the groups.

Conclusion

Our results show that EDR administration lessened hair loss due to CPA in a dose-independent manner above doses of 3%, suggesting potential applications beside chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

Not applicable.

Code availability

Not applicable.

References

  1. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12:543–549. https://doi.org/10.1007/s00520-003-0562-5

    Article  PubMed  Google Scholar 

  2. Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328. https://doi.org/10.1002/pon.1245

    Article  PubMed  Google Scholar 

  3. Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi M (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. J Am Med Assoc 317:596–605. https://doi.org/10.1001/jama.2016.20939

    Article  Google Scholar 

  4. Komen MMC, Smorenburg CH, van den Hurk CJG, Nortier JWR (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18:885–891. https://doi.org/10.1634/theoncologist.2012-0332

    Article  PubMed  PubMed Central  Google Scholar 

  5. Singh K, Bhori M, Kasu YA, Bhat G, Marar T (2018) Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - exploring the armoury of obscurity. Saudi Pharm J 26:177–190. https://doi.org/10.1016/j.jsps.2017.12.013

    Article  PubMed  Google Scholar 

  6. Sato T, Mizuno K, Ishii F (2008) In vitro metabolism study of edaravone in Wistar and hairless rat skin. Biol Pharm Bull 31:1150–1154. https://doi.org/10.1248/bpb.31.1150

    Article  CAS  PubMed  Google Scholar 

  7. Stenn KS, Paus R (2001) Controls of hair follicle cycling. Physiol Rev 81:449–494. https://doi.org/10.1152/physrev.2001.81.1.449

    Article  CAS  PubMed  Google Scholar 

  8. Onaolapo AY, Adebayo AA, Onaolapo OJ (2018) Oral phenytoin protects against experimental cyclophosphamide-chemotherapy induced hair loss. Pathophysiology 25:31–39. https://doi.org/10.1016/j.pathophys.2017.12.001

    Article  CAS  PubMed  Google Scholar 

  9. Hagiwara S, Uchida T, Koga H, Inomata M, Yoshizumi F, Moriyama M, Kitano S, Noguchi T (2011) The α-lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: A pilot study. Surg Today 41:693–697. https://doi.org/10.1007/s00595-010-4481-z

    Article  CAS  PubMed  Google Scholar 

  10. Paus R, Bori H, Eichmüller S, Czarnetzki BM (1994) Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. Am J Pathol 144:719–734

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Schilli MB, Paus R, Menrad A (1998) Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 111:598–604. https://doi.org/10.1046/j.1523-1747.1998.00350.x

    Article  CAS  PubMed  Google Scholar 

  12. Yano K, Brown LF, Detmar M (2001) Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 107:409–417. https://doi.org/10.1172/JCI11317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Müller-Röver S, Handjiski B, van der Veen C, Eichmüller S, Foitzik K, McKay IA, Stenn KS, Paus R (2001) A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 117:3–15. https://doi.org/10.1046/j.0022-202x.2001.01377.x

    Article  PubMed  Google Scholar 

  14. Hendrix S, Bori H, Peters EMJ, Paus R (2005) A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J Invest Dermatol 125:42–51. https://doi.org/10.1111/j.0022-202X.2005.23787.x

    Article  CAS  PubMed  Google Scholar 

  15. Cook JJ, Haynes KM, Werther GA (1988) Mitogenic effects of growth hormone in cultured human fibroblasts. Evidence for action via local insulin-like growth factor I production. J Clin Invest 81:206–212. https://doi.org/10.1172/JCI113296

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rudman SM, Philpott MP, Thomas GA, Kealey T (1997) The role of IGF-I in human skin and its appendages: morphogen as well as mitogen? J Invest Dermatol 109:770–777. https://doi.org/10.1111/1523-1747.ep12340934

    Article  CAS  PubMed  Google Scholar 

  17. Philpott MP, Sanders DA, Kealey T (1994) Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro. J Invest Dermatol 102:857–861. https://doi.org/10.1111/1523-1747.ep12382494

    Article  CAS  PubMed  Google Scholar 

  18. Weger N, Schlake T (2005) IGF-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol 125:873–882. https://doi.org/10.1111/j.0022-202X.2005.23946.x

    Article  CAS  PubMed  Google Scholar 

  19. Schlake T, Beibel M, Weger N, Boehm T (2004) Major shifts in genomic activity accompany progression through different stages of the hair cycle. Gene Expr Patterns 4:141–152. https://doi.org/10.1016/j.modgep.2003.09.009

    Article  CAS  PubMed  Google Scholar 

  20. Wikramanayake TC, Amini S, Simon J, Mauro LM, Elgart G, Schachner LA, Jimenez JJ (2012) A novel rat model for chemotherapy-induced alopecia. Clin Exp Dermatol 37:284–289. https://doi.org/10.1111/j.1365-2230.2011.04239.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Trüeb RM (2009) Chemotherapy-Induced Alopecia. Semin Cutan Med Surg 28:11–14. https://doi.org/10.1016/j.sder.2008.12.001

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka, 573-0101, Japan

    Katsuaki Yoneda, Miyu Fujii, Aoi Imaoka, Remi Kobayashi, Ryoya Hayashi, Yuya Yoshida, Takeyuki Kohno & Takumi Tsuji

  2. Department of Pharmacy, Kouseikai Takai Hospital, 470-8 Kuranosho-cho, Tenri, Nara, 632-0006, Japan

    Katsuaki Yoneda

Authors
  1. Katsuaki Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miyu Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aoi Imaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Remi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryoya Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeyuki Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takumi Tsuji
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Katsuaki Yoneda, Miyu Fujii, Aoi Imaoka, Remi Kobayashi, Ryoya Hayashi, and Takumi Tsuji. The first draft of the manuscript was written by Katsuaki Yoneda and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Takumi Tsuji.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

Approval was obtained from the ethics committee of Setsunan University.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoneda, K., Fujii, M., Imaoka, A. et al. Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy induced alopecia. Support Care Cancer 29, 6127–6134 (2021). https://doi.org/10.1007/s00520-021-06189-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-021-06189-7

Keywords

Search

Navigation